BrainsWay SWIFT Protocol Gains Insurance Coverage for Over 70 Million Lives
BrainsWay Ltd. (TASE:BWAY) announced that favorable U.S. medical policies now cover its SWIFT Accelerated Deep TMS protocol for more than 70 million lives. The expanded coverage applies to the company's treatment of major depressive disorder and obsessive-compulsive disorder.
The broader payer acceptance increases the reimbursable patient pool for clinics using Deep TMS technology. By reducing out-of-pocket costs for patients, favorable insurance policies help stimulate clinic adoption and support steady demand for core FDA-cleared indications.
Going forward, key indicators to monitor include announcements of specific insurance carrier agreements, additional policy decisions, and any clear impact on treatment volume and corporate revenue.
Key points
- BrainsWay Ltd. secured U.S. medical policy coverage for over 70 million lives for its SWIFT Accelerated Deep TMS protocol.
- The coverage updates apply to treatment for major depressive disorder and obsessive-compulsive disorder.
- Broader insurance acceptance expands the reimbursable patient base, supporting clinic demand and utilization.
- BrainsWay shares rose 3.47 percent to 3,668 ILA following the update.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the new coverage benchmark for BrainsWay SWIFT protocol?
U.S. medical policies now cover the SWIFT Accelerated Deep TMS protocol for over 70 million lives across core mental health indications.
Which medical conditions does BrainsWay SWIFT protocol treat?
The protocol is covered for FDA-cleared indications including major depressive disorder and obsessive-compulsive disorder.
How did BrainsWay stock react to the coverage news?
BrainsWay Ltd. stock traded up 3.47 percent to 3,668 ILA.